The efficacy of imatinib, a multityrosine kinase inhibitor, in patients with GIST presenting germline <i>KIT</i> variants has been poorly reported, and the efficacy in clinical trials of treatments with tyrosine kinase inhibitors remains unclear. This evidence concerns the gene KIT and gastrointestinal stromal tumor.